Most US adults with type 2 diabetes meet criteria for GLP-RAs, SGLT2is
Feb 28, 2023
More than 82% US adults with type 2 diabetes meet the criteria to be prescribed the drugs, yet only 9% use either of them.
Pfizer asks FDA to approve omicron-specific booster shot
Aug 22, 2022
The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.
More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
New benefits for certain COVID-19 patients, including reduced need for respiratory intervention, have been found for Merck’s COVID-19 pill molnupiravir.
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
– A high burden of persistent symptoms is observed in persons after COVID-19, but no specific causes of symptoms of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)...